Transenterix (TRXC) vs. Antares Pharma (ATRS) Head to Head Review
Transenterix (NYSE: TRXC) and Antares Pharma (NASDAQ:ATRS) are both small-cap medical equipment, supplies & distribution – nec companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.
Insider and Institutional Ownership
36.8% of Antares Pharma shares are held by institutional investors. 11.6% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for Transenterix and Antares Pharma, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Transenterix currently has a consensus price target of $3.38, suggesting a potential upside of 18.84%. Antares Pharma has a consensus price target of $3.95, suggesting a potential upside of 110.11%. Given Antares Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Antares Pharma is more favorable than Transenterix.
This table compares Transenterix and Antares Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Transenterix has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500.
Earnings and Valuation
This table compares Transenterix and Antares Pharma’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Antares Pharma||$52.22 million||5.63||-$24.33 million||($0.12)||-15.67|
Transenterix has higher revenue, but lower earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Transenterix, indicating that it is currently the more affordable of the two stocks.
Antares Pharma beats Transenterix on 11 of the 12 factors compared between the two stocks.
TransEnterix, Inc. is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. The SurgiBot System is designed as a single-incision, patient-side robotic-assisted surgery system. The Company also develops and manufactures laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments.
About Antares Pharma
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.